Loading
A phase 2 trial of Pembrolizumab in colorectal cancer, run by Vividion Therapeutics, Inc., now recruiting.
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum is a phase 2 interventional study registered as NCT07811193 by Vividion Therapeutics, Inc., with 140 participants planned, started 2026-09-11 and due to reach its primary completion in 2028-06-30. Interventions recorded: VVD-133214 and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Rectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/